Global Oncology Biosimilar Market to Reach USD 36.90 Billion by 2034 at a CAGR of 18.5%
The global Oncology Biosimilar Market is projected to witness robust growth through the forecast period, expanding from an estimated USD 9.48 billion in 2026 to USD 36.90 billion by 2034 at a CAGR of 18.5%. The growth is driven by rising cancer incidence, patent expiries of blockbuster biologics, and increasing adoption of cost-effective biosimilar therapies worldwide.